查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1631230

導管相關泌尿道感染治療的全球市場 - 全球產業分析，規模，佔有率，成長，趨勢，預測(2032年)

Catheter Associated Urinary Tract Infections Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032
出版日期: | 出版商: Fairfield Market Research | 英文 216 Pages | 商品交期: 2-5個工作天內

價格
簡介目錄

受治療方法的進步、創新的藥物方案以及感染預防意識的不斷提高的推動，全球導管相關尿道感染 (CAUTI) 治療市場預計將出現顯著增長。 CAUTI 是醫療保健環境中的常見併發症，需要有針對性的治療介入來管理和預防與導尿管使用相關的細菌感染。

市場洞察

預計到 2025 年，CAUTI 治療市場規模將達到 15 億美元，到 2032 年將進一步擴大至 19.3 億美元，複合年增長率為 3.60%。由於醫療機構廣泛使用導尿管以及對抗生素抗藥性的擔憂日益增加，導致 CAUTI 盛行率不斷上升，影響了市場的成長軌跡。由於治療技術的進步和對感染預防的日益重視，全球導管相關泌尿道感染治療市場具有巨大的成長潛力。透過對研發和協作努力的策略性投資，領先的公司能夠很好地應對 CAUTI 管理不斷變化的課題，確保改善患者的治療效果並持續擴大市場。此外，家庭醫療保健和遠距醫療的興起凸顯了可訪問和創新的治療解決方案的重要性，為未來幾年的變革性醫療保健分析鋪平了道路。

全球人口老化將增加對導尿管和有效感染控制的需求，從而推動市場成長。創新抗生素、防腐劑和抗感染導管材料的開發克服了傳統治療的課題並改善了患者的治療效果。傳統抗生素抗藥性的增強為新的治療方法創造了機會，例如抗菌塗層和替代藥物配方。

本報告提供全球導管相關泌尿道感染治療市場相關調查，提供市場概要，以及各藥物類型，各適應症類型，各流通管道，及各地區趨勢，及市場參與市場企業的競爭趨勢等資訊。

目錄

第1章 摘要整理

第2章 市場概要

  • 市場定義和市場區隔
  • 市場動態
  • 價值鏈分析
  • 波特的五力分析
  • COVID-19影響分析
  • 烏克蘭·俄羅斯糾紛的影響
  • 經濟概要
  • 大環境分析

第3章 全球導管相關泌尿道感染治療市場預測，2019年～2032年

  • 全球導管相關泌尿道感染治療市場預測，各藥物類型，金額(10億美元)，2019年～2032年
  • 全球導管相關泌尿道感染治療市場預測，各適應症類型，金額(10億美元)，2019年～2032年
  • 全球導管相關泌尿道感染治療市場預測，各流通管道，金額(10億美元)，2019年～2032年
  • 全球導管相關泌尿道感染治療市場預測，各地區，金額(10億美元)，2019年～2032年

第4章 北美的導管相關泌尿道感染治療市場預測，2019年～2032年

第5章 歐洲的導管相關泌尿道感染治療市場預測，2019年～2032年

第6章 亞太地區的導管相關泌尿道感染治療市場預測，2019年～2032年

第7章 南美的導管相關泌尿道感染治療市場預測，2019年～2032年

第8章 中東·非洲的導管相關泌尿道感染治療市場預測，2019年～2032年

第9章 競爭情形

  • 各流通管道和各適應症類型的熱圖
  • 各製造廠商和各適應症類型的熱圖
  • 企業市場佔有率分析，2024年
  • 競爭儀表板
  • 企業簡介
    • Pfizer Inc.
    • Merck & Co., Inc.
    • GlaxoSmithKline (GSK)
    • AstraZeneca
    • Bayer AG
    • Johnson & Johnson
    • Novartis International AG
    • Sanofi
    • Roche Holding AG
    • Eli Lilly and Company
    • Bristol-Myers Squibb Company
    • Abbott Laboratories
    • Astellas Pharma Inc.
    • Boehringer Ingelheim
    • Daiichi Sankyo Company, Limited
    • Gilead Sciences, Inc.

第10章 附錄

簡介目錄

The global catheter-associated urinary tract infections (CAUTIs) treatment market is poised for significant growth, driven by advancements in treatment modalities, innovative drug formulations, and increasing awareness of infection prevention. CAUTIs, a prevalent complication in healthcare settings, necessitate targeted therapeutic interventions to manage and prevent bacterial infections associated with urinary catheter use.

Market Insights

The CAUTIs treatment market is expected to reach a value of $1.50 billion by 2025 and expand further to $1.93 billion by 2032, registering a compound annual growth rate (CAGR) of 3.60%. The market's growth trajectory is influenced by the increasing prevalence of CAUTIs, driven by the widespread use of urinary catheters in healthcare facilities, and the rising concern of antibiotic resistance. The global catheter-associated urinary tract infections treatment market offers significant growth potential, driven by advancements in therapeutic technologies and a growing focus on infection prevention. With strategic investments in R&D and collaborative efforts, key players are poised to address the evolving challenges of CAUTI management, ensuring improved patient outcomes and sustained market expansion. Furthermore, the rise of home healthcare and telemedicine underscores the importance of accessible and innovative treatment solutions, paving the way for a transformative healthcare Analysis in the years ahead.

Key Market Drivers

  • 1. Expanding Aging Population: The aging global population increases the demand for urinary catheters and effective infection management, boosting market growth.
  • 2. Advancements in Treatment Modalities: The development of innovative antibiotics, antiseptics, and infection-resistant catheter materials addresses the challenges of traditional therapies and improves patient outcomes.
  • 3. Antibiotic Resistance: The rising resistance to conventional antibiotics creates opportunities for novel therapeutic approaches, including antimicrobial coatings and alternative drug formulations.

Business Opportunities

  • 1. Rise in Home Healthcare and Telemedicine: The growing trend of home healthcare and remote medical services calls for patient-friendly and self-administered treatment options for CAUTIs. These approaches address the unique needs of patients outside traditional healthcare settings, providing significant market potential.
  • 2. Antimicrobial Coatings for Catheters: Technological advancements in catheters with controlled-release antimicrobial coatings present lucrative revenue opportunities, addressing both prevention and treatment needs. The integration of antimicrobial technologies in catheter design minimizes bacterial colonization risks, enhancing patient safety.
  • 3. Collaborative Research: Partnerships between pharmaceutical companies, healthcare providers, and research institutions drive innovation in CAUTI treatments, enhancing market dynamics. These collaborations foster the development of advanced therapeutic solutions tailored to emerging healthcare challenges.

Regional Analysis

  • Europe: Dominates the market due to advanced healthcare infrastructure, robust research initiatives, and strategic collaborations that drive innovation. Regulatory support and funding for infection control further bolster Europe's market leadership.
  • South Asia & Pacific: Emerges as the fastest-growing region, fueled by population expansion, increasing awareness, and evolving healthcare infrastructure. The adoption of modern healthcare practices and government-backed programs support market growth in this region.
  • North America: Maintains a strong market presence owing to well-established healthcare systems and significant investment in medical research. The region's focus on technological integration enhances CAUTI treatment strategies.

Key Players

Prominent companies shaping the CAUTIs treatment market include:

  • Pfizer Inc.
  • Merck & Co., Inc.
  • GlaxoSmithKline (GSK)
  • AstraZeneca
  • Bayer AG
  • Johnson & Johnson
  • Novartis International AG
  • Sanofi
  • Roche Holding AG
  • Abbott Laboratories
  • Bristol-Myers Squibb Company
  • Astellas Pharma Inc.
  • Eli Lilly and Company
  • Teva Pharmaceutical Industries Ltd.
  • Sun Pharmaceutical Industries Ltd.

Market Segmentation

1. By Drug Type:

    Penicillin & Combinations Quinolones Cephalosporins Aminoglycoside Antibiotics Sulphonamides Azoles and Amphotericin B Tetracycline Nitrofurantoin

2. By Indication Type:

    Asymptomatic CAUTI (Bacteriuria) Symptomatic CAUTI (Bacteremic)

3. By Distribution Channel:

    Hospital Pharmacies Gynecology and Urology Clinics Drug Stores Retail Pharmacies Online Drug Stores

4. By Region:

    North America Europe Asia Pacific Latin America Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Catheter Associated Urinary Tract Infections Treatment Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2024
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Catheter Associated Urinary Tract Infections Treatment Market Outlook, 2019 - 2032

  • 3.1. Global Catheter Associated Urinary Tract Infections Treatment Market Outlook, by Drug Type, Value (US$ Bn), 2019 - 2032
    • 3.1.1. Key Highlights
      • 3.1.1.1. Penicillin & Combinations
      • 3.1.1.2. Quinolones
      • 3.1.1.3. Caphalosporin
      • 3.1.1.4. Aminoglycoside Antibiotics
      • 3.1.1.5. Sulphonamides
      • 3.1.1.6. Azoles and Amphotericin B
      • 3.1.1.7. Tetracycline
      • 3.1.1.8. Nitrofura
  • 3.2. Global Catheter Associated Urinary Tract Infections Treatment Market Outlook, by Indication Type, Value (US$ Bn), 2019 - 2032
    • 3.2.1. Key Highlights
      • 3.2.1.1. Asymptomatic CAUTI (Bacteriuria)
      • 3.2.1.2. Symptomatic CAUTI (Bacteremic)
  • 3.3. Global Catheter Associated Urinary Tract Infections Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 3.3.1. Key Highlights
      • 3.3.1.1. Hospital Pharmacies
      • 3.3.1.2. Gynaecology and Urology Clinics
      • 3.3.1.3. Drug Stores
      • 3.3.1.4. Retail Pharmacies
      • 3.3.1.5. Online Drug Stores
  • 3.4. Global Catheter Associated Urinary Tract Infections Treatment Market Outlook, by Region, Value (US$ Bn), 2019 - 2032
    • 3.4.1. Key Highlights
      • 3.4.1.1. North America
      • 3.4.1.2. Europe
      • 3.4.1.3. Asia Pacific
      • 3.4.1.4. Latin America
      • 3.4.1.5. Middle East & Africa

4. North America Catheter Associated Urinary Tract Infections Treatment Market Outlook, 2019 - 2032

  • 4.1. North America Catheter Associated Urinary Tract Infections Treatment Market Outlook, by Drug Type, Value (US$ Bn), 2019 - 2032
    • 4.1.1. Key Highlights
      • 4.1.1.1. Penicillin & Combinations
      • 4.1.1.2. Quinolones
      • 4.1.1.3. Cephalosporin
      • 4.1.1.4. Aminoglycoside Antibiotics
      • 4.1.1.5. Sulphonamides
      • 4.1.1.6. Azoles and Amphotericin B
      • 4.1.1.7. Tetracycline
      • 4.1.1.8. Nitrofura
  • 4.2. North America Catheter Associated Urinary Tract Infections Treatment Market Outlook, by Indication Type, Value (US$ Bn), 2019 - 2032
    • 4.2.1. Key Highlights
      • 4.2.1.1. Asymptomatic CAUTI (Bacteriuria)
      • 4.2.1.2. Symptomatic CAUTI (Bacteremic)
  • 4.3. North America Catheter Associated Urinary Tract Infections Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 4.3.1. Key Highlights
      • 4.3.1.1. Hospital Pharmacies
      • 4.3.1.2. Gynaecology and Urology Clinics
      • 4.3.1.3. Drug Stores
      • 4.3.1.4. Retail Pharmacies
      • 4.3.1.5. Online Drug Stores
    • 4.3.2. BPS Analysis/Market Attractiveness Analysis
  • 4.4. North America Catheter Associated Urinary Tract Infections Treatment Market Outlook, by Country, Value (US$ Bn), 2019 - 2032
    • 4.4.1. Key Highlights
      • 4.4.1.1. U.S. Catheter Associated Urinary Tract Infections Treatment Market by Drug Type, Value (US$ Bn), 2019 - 2032
      • 4.4.1.2. U.S. Catheter Associated Urinary Tract Infections Treatment Market by Indication Type, Value (US$ Bn), 2019 - 2032
      • 4.4.1.3. U.S. Catheter Associated Urinary Tract Infections Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 4.4.1.4. Canada Catheter Associated Urinary Tract Infections Treatment Market by Drug Type, Value (US$ Bn), 2019 - 2032
      • 4.4.1.5. Canada Catheter Associated Urinary Tract Infections Treatment Market by Indication Type, Value (US$ Bn), 2019 - 2032
      • 4.4.1.6. Canada Catheter Associated Urinary Tract Infections Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 4.4.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Catheter Associated Urinary Tract Infections Treatment Market Outlook, 2019 - 2032

  • 5.1. Europe Catheter Associated Urinary Tract Infections Treatment Market Outlook, by Drug Type, Value (US$ Bn), 2019 - 2032
    • 5.1.1. Key Highlights
      • 5.1.1.1. Penicillin & Combinations
      • 5.1.1.2. Quinolones
      • 5.1.1.3. Cephalosporin
      • 5.1.1.4. Aminoglycoside Antibiotics
      • 5.1.1.5. Sulphonamides
      • 5.1.1.6. Azoles and Amphotericin B
      • 5.1.1.7. Tetracycline
      • 5.1.1.8. Nitrofura
  • 5.2. Europe Catheter Associated Urinary Tract Infections Treatment Market Outlook, by Indication Type, Value (US$ Bn), 2019 - 2032
    • 5.2.1. Key Highlights
      • 5.2.1.1. Asymptomatic CAUTI (Bacteriuria)
      • 5.2.1.2. Symptomatic CAUTI (Bacteremic)
  • 5.3. Europe Catheter Associated Urinary Tract Infections Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 5.3.1. Key Highlights
      • 5.3.1.1. Hospital Pharmacies
      • 5.3.1.2. Gynaecology and Urology Clinics
      • 5.3.1.3. Drug Stores
      • 5.3.1.4. Retail Pharmacies
      • 5.3.1.5. Online Drug Stores
    • 5.3.2. BPS Analysis/Market Attractiveness Analysis
  • 5.4. Europe Catheter Associated Urinary Tract Infections Treatment Market Outlook, by Country, Value (US$ Bn), 2019 - 2032
    • 5.4.1. Key Highlights
      • 5.4.1.1. Germany Catheter Associated Urinary Tract Infections Treatment Market by Drug Type, Value (US$ Bn), 2019 - 2032
      • 5.4.1.2. Germany Catheter Associated Urinary Tract Infections Treatment Market by Indication Type, Value (US$ Bn), 2019 - 2032
      • 5.4.1.3. Germany Catheter Associated Urinary Tract Infections Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 5.4.1.4. U.K. Catheter Associated Urinary Tract Infections Treatment Market by Drug Type, Value (US$ Bn), 2019 - 2032
      • 5.4.1.5. U.K. Catheter Associated Urinary Tract Infections Treatment Market by Indication Type, Value (US$ Bn), 2019 - 2032
      • 5.4.1.6. U.K. Catheter Associated Urinary Tract Infections Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 5.4.1.7. France Catheter Associated Urinary Tract Infections Treatment Market by Drug Type, Value (US$ Bn), 2019 - 2032
      • 5.4.1.8. France Catheter Associated Urinary Tract Infections Treatment Market by Indication Type, Value (US$ Bn), 2019 - 2032
      • 5.4.1.9. France Catheter Associated Urinary Tract Infections Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 5.4.1.10. Italy Catheter Associated Urinary Tract Infections Treatment Market by Drug Type, Value (US$ Bn), 2019 - 2032
      • 5.4.1.11. Italy Catheter Associated Urinary Tract Infections Treatment Market by Indication Type, Value (US$ Bn), 2019 - 2032
      • 5.4.1.12. Italy Catheter Associated Urinary Tract Infections Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 5.4.1.13. Turkey Catheter Associated Urinary Tract Infections Treatment Market by Drug Type, Value (US$ Bn), 2019 - 2032
      • 5.4.1.14. Turkey Catheter Associated Urinary Tract Infections Treatment Market by Indication Type, Value (US$ Bn), 2019 - 2032
      • 5.4.1.15. Turkey Catheter Associated Urinary Tract Infections Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 5.4.1.16. Russia Catheter Associated Urinary Tract Infections Treatment Market by Drug Type, Value (US$ Bn), 2019 - 2032
      • 5.4.1.17. Russia Catheter Associated Urinary Tract Infections Treatment Market by Indication Type, Value (US$ Bn), 2019 - 2032
      • 5.4.1.18. Russia Catheter Associated Urinary Tract Infections Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 5.4.1.19. Rest of Europe Catheter Associated Urinary Tract Infections Treatment Market by Drug Type, Value (US$ Bn), 2019 - 2032
      • 5.4.1.20. Rest of Europe Catheter Associated Urinary Tract Infections Treatment Market by Indication Type, Value (US$ Bn), 2019 - 2032
      • 5.4.1.21. Rest of Europe Catheter Associated Urinary Tract Infections Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 5.4.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Catheter Associated Urinary Tract Infections Treatment Market Outlook, 2019 - 2032

  • 6.1. Asia Pacific Catheter Associated Urinary Tract Infections Treatment Market Outlook, by Drug Type, Value (US$ Bn), 2019 - 2032
    • 6.1.1. Key Highlights
      • 6.1.1.1. Penicillin & Combinations
      • 6.1.1.2. Quinolones
      • 6.1.1.3. Cephalosporin
      • 6.1.1.4. Aminoglycoside Antibiotics
      • 6.1.1.5. Sulphonamides
      • 6.1.1.6. Azoles and Amphotericin B
      • 6.1.1.7. Tetracycline
      • 6.1.1.8. Nitrofura
  • 6.2. Asia Pacific Catheter Associated Urinary Tract Infections Treatment Market Outlook, by Indication Type, Value (US$ Bn), 2019 - 2032
    • 6.2.1. Key Highlights
      • 6.2.1.1. Asymptomatic CAUTI (Bacteriuria)
      • 6.2.1.2. Symptomatic CAUTI (Bacteremic)
  • 6.3. Asia Pacific Catheter Associated Urinary Tract Infections Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 6.3.1. Key Highlights
      • 6.3.1.1. Hospital Pharmacies
      • 6.3.1.2. Gynaecology and Urology Clinics
      • 6.3.1.3. Drug Stores
      • 6.3.1.4. Retail Pharmacies
      • 6.3.1.5. Online Drug Stores
    • 6.3.2. BPS Analysis/Market Attractiveness Analysis
  • 6.4. Asia Pacific Catheter Associated Urinary Tract Infections Treatment Market Outlook, by Country, Value (US$ Bn), 2019 - 2032
    • 6.4.1. Key Highlights
      • 6.4.1.1. China Catheter Associated Urinary Tract Infections Treatment Market by Drug Type, Value (US$ Bn), 2019 - 2032
      • 6.4.1.2. China Catheter Associated Urinary Tract Infections Treatment Market by Indication Type, Value (US$ Bn), 2019 - 2032
      • 6.4.1.3. China Catheter Associated Urinary Tract Infections Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 6.4.1.4. Japan Catheter Associated Urinary Tract Infections Treatment Market by Drug Type, Value (US$ Bn), 2019 - 2032
      • 6.4.1.5. Japan Catheter Associated Urinary Tract Infections Treatment Market by Indication Type, Value (US$ Bn), 2019 - 2032
      • 6.4.1.6. Japan Catheter Associated Urinary Tract Infections Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 6.4.1.7. South Korea Catheter Associated Urinary Tract Infections Treatment Market by Drug Type, Value (US$ Bn), 2019 - 2032
      • 6.4.1.8. South Korea Catheter Associated Urinary Tract Infections Treatment Market by Indication Type, Value (US$ Bn), 2019 - 2032
      • 6.4.1.9. South Korea Catheter Associated Urinary Tract Infections Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 6.4.1.10. India Catheter Associated Urinary Tract Infections Treatment Market by Drug Type, Value (US$ Bn), 2019 - 2032
      • 6.4.1.11. India Catheter Associated Urinary Tract Infections Treatment Market by Indication Type, Value (US$ Bn), 2019 - 2032
      • 6.4.1.12. India Catheter Associated Urinary Tract Infections Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 6.4.1.13. Southeast Asia Catheter Associated Urinary Tract Infections Treatment Market by Drug Type, Value (US$ Bn), 2019 - 2032
      • 6.4.1.14. Southeast Asia Catheter Associated Urinary Tract Infections Treatment Market by Indication Type, Value (US$ Bn), 2019 - 2032
      • 6.4.1.15. Southeast Asia Catheter Associated Urinary Tract Infections Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 6.4.1.16. Rest of Asia Pacific Catheter Associated Urinary Tract Infections Treatment Market by Drug Type, Value (US$ Bn), 2019 - 2032
      • 6.4.1.17. Rest of Asia Pacific Catheter Associated Urinary Tract Infections Treatment Market by Indication Type, Value (US$ Bn), 2019 - 2032
      • 6.4.1.18. Rest of Asia Pacific Catheter Associated Urinary Tract Infections Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 6.4.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Catheter Associated Urinary Tract Infections Treatment Market Outlook, 2019 - 2032

  • 7.1. Latin America Catheter Associated Urinary Tract Infections Treatment Market Outlook, by Drug Type, Value (US$ Bn), 2019 - 2032
    • 7.1.1. Key Highlights
      • 7.1.1.1. Penicillin & Combinations
      • 7.1.1.2. Quinolones
      • 7.1.1.3. Cephalosporin
      • 7.1.1.4. Aminoglycoside Antibiotics
      • 7.1.1.5. Sulphonamides
      • 7.1.1.6. Azoles and Amphotericin B
      • 7.1.1.7. Tetracycline
      • 7.1.1.8. Nitrofura
  • 7.2. Latin America Catheter Associated Urinary Tract Infections Treatment Market Outlook, by Indication Type, Value (US$ Bn), 2019 - 2032
      • 7.2.1.1. Asymptomatic CAUTI (Bacteriuria)
      • 7.2.1.2. Symptomatic CAUTI (Bacteremic)
  • 7.3. Latin America Catheter Associated Urinary Tract Infections Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 7.3.1. Key Highlights
      • 7.3.1.1. Hospital Pharmacies
      • 7.3.1.2. Gynaecology and Urology Clinics
      • 7.3.1.3. Drug Stores
      • 7.3.1.4. Retail Pharmacies
      • 7.3.1.5. Online Drug Stores
    • 7.3.2. BPS Analysis/Market Attractiveness Analysis
  • 7.4. Latin America Catheter Associated Urinary Tract Infections Treatment Market Outlook, by Country, Value (US$ Bn), 2019 - 2032
    • 7.4.1. Key Highlights
      • 7.4.1.1. Brazil Catheter Associated Urinary Tract Infections Treatment Market by Drug Type, Value (US$ Bn), 2019 - 2032
      • 7.4.1.2. Brazil Catheter Associated Urinary Tract Infections Treatment Market by Indication Type, Value (US$ Bn), 2019 - 2032
      • 7.4.1.3. Brazil Catheter Associated Urinary Tract Infections Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 7.4.1.4. Mexico Catheter Associated Urinary Tract Infections Treatment Market by Drug Type, Value (US$ Bn), 2019 - 2032
      • 7.4.1.5. Mexico Catheter Associated Urinary Tract Infections Treatment Market by Indication Type, Value (US$ Bn), 2019 - 2032
      • 7.4.1.6. Mexico Catheter Associated Urinary Tract Infections Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 7.4.1.7. Argentina Catheter Associated Urinary Tract Infections Treatment Market by Drug Type, Value (US$ Bn), 2019 - 2032
      • 7.4.1.8. Argentina Catheter Associated Urinary Tract Infections Treatment Market by Indication Type, Value (US$ Bn), 2019 - 2032
      • 7.4.1.9. Argentina Catheter Associated Urinary Tract Infections Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 7.4.1.10. Rest of Latin America Catheter Associated Urinary Tract Infections Treatment Market by Drug Type, Value (US$ Bn), 2019 - 2032
      • 7.4.1.11. Rest of Latin America Catheter Associated Urinary Tract Infections Treatment Market by Indication Type, Value (US$ Bn), 2019 - 2032
      • 7.4.1.12. Rest of Latin America Catheter Associated Urinary Tract Infections Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 7.4.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Catheter Associated Urinary Tract Infections Treatment Market Outlook, 2019 - 2032

  • 8.1. Middle East & Africa Catheter Associated Urinary Tract Infections Treatment Market Outlook, by Drug Type, Value (US$ Bn), 2019 - 2032
    • 8.1.1. Key Highlights
      • 8.1.1.1. Penicillin & Combinations
      • 8.1.1.2. Quinolones
      • 8.1.1.3. Cephalosporin
      • 8.1.1.4. Aminoglycoside Antibiotics
      • 8.1.1.5. Sulphonamides
      • 8.1.1.6. Azoles and Amphotericin B
      • 8.1.1.7. Tetracycline
      • 8.1.1.8. Nitrofura
  • 8.2. Middle East & Africa Catheter Associated Urinary Tract Infections Treatment Market Outlook, by Indication Type, Value (US$ Bn), 2019 - 2032
    • 8.2.1. Key Highlights
      • 8.2.1.1. Asymptomatic CAUTI (Bacteriuria)
      • 8.2.1.2. Symptomatic CAUTI (Bacteremic)
  • 8.3. Middle East & Africa Catheter Associated Urinary Tract Infections Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 8.3.1. Key Highlights
      • 8.3.1.1. Hospital Pharmacies
      • 8.3.1.2. Gynaecology and Urology Clinics
      • 8.3.1.3. Drug Stores
      • 8.3.1.4. Retail Pharmacies
      • 8.3.1.5. Online Drug Stores
    • 8.3.2. BPS Analysis/Market Attractiveness Analysis
  • 8.4. Middle East & Africa Catheter Associated Urinary Tract Infections Treatment Market Outlook, by Country, Value (US$ Bn), 2019 - 2032
    • 8.4.1. Key Highlights
      • 8.4.1.1. GCC Catheter Associated Urinary Tract Infections Treatment Market by Drug Type, Value (US$ Bn), 2019 - 2032
      • 8.4.1.2. GCC Catheter Associated Urinary Tract Infections Treatment Market by Indication Type, Value (US$ Bn), 2019 - 2032
      • 8.4.1.3. GCC Catheter Associated Urinary Tract Infections Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 8.4.1.4. South Africa Catheter Associated Urinary Tract Infections Treatment Market by Drug Type, Value (US$ Bn), 2019 - 2032
      • 8.4.1.5. South Africa Catheter Associated Urinary Tract Infections Treatment Market by Indication Type, Value (US$ Bn), 2019 - 2032
      • 8.4.1.6. South Africa Catheter Associated Urinary Tract Infections Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 8.4.1.7. Egypt Catheter Associated Urinary Tract Infections Treatment Market by Drug Type, Value (US$ Bn), 2019 - 2032
      • 8.4.1.8. Egypt Catheter Associated Urinary Tract Infections Treatment Market by Indication Type, Value (US$ Bn), 2019 - 2032
      • 8.4.1.9. Egypt Catheter Associated Urinary Tract Infections Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 8.4.1.10. Nigeria Catheter Associated Urinary Tract Infections Treatment Market by Drug Type, Value (US$ Bn), 2019 - 2032
      • 8.4.1.11. Nigeria Catheter Associated Urinary Tract Infections Treatment Market by Indication Type, Value (US$ Bn), 2019 - 2032
      • 8.4.1.12. Nigeria Catheter Associated Urinary Tract Infections Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 8.4.1.13. Rest of Middle East & Africa Catheter Associated Urinary Tract Infections Treatment Market by Drug Type, Value (US$ Bn), 2019 - 2032
      • 8.4.1.14. Rest of Middle East & Africa Catheter Associated Urinary Tract Infections Treatment Market by Indication Type, Value (US$ Bn), 2019 - 2032
      • 8.4.1.15. Rest of Middle East & Africa Catheter Associated Urinary Tract Infections Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 8.4.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. By Distribution Channel vs by Indication Type Heat map
  • 9.2. Manufacturer vs by Indication Type Heatmap
  • 9.3. Company Market Share Analysis, 2024
  • 9.4. Competitive Dashboard
  • 9.5. Company Profiles
    • 9.5.1. Pfizer Inc.
      • 9.5.1.1. Company Overview
      • 9.5.1.2. Product Portfolio
      • 9.5.1.3. Financial Overview
      • 9.5.1.4. Business Strategies and Development
    • 9.5.2. Merck & Co., Inc.
    • 9.5.3. GlaxoSmithKline (GSK)
    • 9.5.4. AstraZeneca
    • 9.5.5. Bayer AG
    • 9.5.6. Johnson & Johnson
    • 9.5.7. Novartis International AG
    • 9.5.8. Sanofi
    • 9.5.9. Roche Holding AG
    • 9.5.10. Eli Lilly and Company
    • 9.5.11. Bristol-Myers Squibb Company
    • 9.5.12. Abbott Laboratories
    • 9.5.13. Astellas Pharma Inc.
    • 9.5.14. Boehringer Ingelheim
    • 9.5.15. Daiichi Sankyo Company, Limited
    • 9.5.16. Gilead Sciences, Inc.

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations